Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental Disorders
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A retrospective study was conducted to assess the effectiveness and tolerability of atomoxetine in children and adolescents with pervasive developmental disorders (PDD). An outpatient clinic registry of individuals with PDD was used to identify all children and adolescents who received atomoxetine over a period of 12 months. Patients were included if concomitant medications remained unchanged. Treatment response was assessed using the Global Improvement item of the Clinical Global Impressions scale (CGI-GI) based on the Conners Parent Rating Scale (CPRS) routinely completed by primary caretakers and other clinical information available in the registry. Twenty patients were identified, including 16 males and 4 females (age, 11.5 years; standard deviation, 3.5). Most patients (80%) were taking at least 1 concomitant medication. Treatment dose was 43.3 mg (standard deviation, 18.1) and duration was 19.5 weeks (standard deviation, 10.5). Twelve patients were judged to be responders, as defined by a score of 1 or 2 on the CGI-GI. Differences between baseline and the end of the trial period were observed in the following CPRS subscales: Conduct, hyperactivity, inattention, and learning. No differences were noted in the anxiety and psychosomatic subscales. One patient discontinued atomoxetine because of severe mood swings. Atomoxetine may be beneficial for treating secondary symptoms of PDD, and prospective open-label or double-blind, placebo-controlled studies are needed to assess its efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Comorbid anxiety symptoms in children with pervasive developmental disorders
Muris, P., Steerneman, P., Merckelbach, H., Holdrinet, I., & Meesters, C. (1998) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(98)00022-x · Cited by 368
Cited by
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260
Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R.-J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.04.011 · Cited by 171
Guanfacine in children with autism and/or intellectual disabilities
Handen, B. L., Sahl, R., & Hardan, A. Y. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181739b9d · Cited by 126
Self-citationPosey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.599 · Cited by 117
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders
Aman, M. G., Farmer, C. A., Hollway, J., & Arnold, L. E. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.009 · Cited by 82
Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder
Hazell, P. (2007) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2007.00995.x · Cited by 69
Atomoxetine for Treating ADHD Symptoms in Autism: A Systematic Review
Ghanizadeh, A. (2013) · Journal of Attention Disorders · doi:10.1177/1087054712443154 · Cited by 43
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders
Wink, L. K., Plawecki, M. H., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.487860 · Cited by 36
Zeiner, P., Gjevik, E., & Weidle, B. (2011) · Acta Paediatrica · doi:10.1111/j.1651-2227.2011.02263.x · Cited by 36
Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder
Handen, B. L., Taylor, J., & Tumuluru, R. (2011) · ijamh · doi:10.1515/ijamh.2011.039 · Cited by 26
Self-citation
Metadata
- Authors
- Jou, R. J., Handen, B. L., & Hardan, A. Y.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-04
- Volume
- 15
- Issue
- 2
- Pages
- 325-330
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2085347131
- Cited by
- 67
- References
- 2
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.